Identification of a Primary Renal AT<sub>2</sub> Receptor Defect in Spontaneously Hypertensive Rats.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31997705.
- Also identified by DOI 10.1161/CIRCRESAHA.119.316193 and PMC identifier 7112539.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Previous studies identified a defect in Ang III (angiotensin III [des-aspartyl<sup>1</sup>-angiotensin II])-elicited AT<sub>2</sub>R (Ang type-2 receptor)-mediated natriuresis in renal proximal tubule cells of spontaneously hypertensive rats (SHR). This study aimed to delineate in prehypertensive SHR kidneys the receptor or postreceptor defect causing impaired AT<sub>2</sub>R signaling and renal sodium (Na<sup>+</sup>) retention by utilizing the selective AT<sub>2</sub>R agonist compound-21 (C-21). Female 4-week-old Wistar Kyoto and SHR rats were studied after 24-hour systemic AT<sub>1</sub>R (Ang II type-1 receptor) blockade. Left kidneys received 30-minute renal interstitial infusions of vehicle followed by C-21 (20, 40, and 60 ng/[kg·min], each dose 30 minutes). Right kidneys received vehicle infusions. In Wistar Kyoto, C-21 dose-dependently increased urine Na<sup>+</sup> excretion from 0.023±0.01 to 0.064±0.02, 0.087±0.01, and 0.089±0.01 µmol/min (<i>P</i>=0.008, <i>P</i><0.0001, and <i>P</i><0.0001, respectively) and renal interstitial fluid levels of AT<sub>2</sub>R downstream signaling molecule cGMP (cyclic guanosine 3',5' monophosphate) from 0.91±0.3 to 3.1±1.0, 5.9±1.2 and 5.3±0.5 fmol/mL (<i>P</i>=nonsignificant, <i>P</i><0.0001, and <i>P</i><0.0001, respectively). In contrast, C-21 did not increase urine Na<sup>+</sup> excretion or renal interstitial cGMP in SHR. Mean arterial pressure was slightly higher in SHR but within the normotensive range and unaffected by C-21. In Wistar Kyoto, but not SHR, C-21 induced AT<sub>2</sub>R translocation to apical plasma membranes of renal proximal tubule cells, internalization/inactivation of NHE-3 (sodium-hydrogen exchanger-3) and Na<sup>+</sup>/K<sup>+</sup>ATPase (sodium-potassium-atpase) and phosphorylation of AT<sub>2</sub>R-cGMP downstream signaling molecules Src (Src family kinase), ERK (extracellular signal-related kinase), and VASP (vasodilator-stimulated phosphoprotein). To test whether cGMP could bypass the natriuretic defect in SHR, we infused 8-bromo-cGMP. This restored natriuresis, Na<sup>+</sup> transporter internalization/inactivation, and Src and VASP phosphorylation, but not apical plasma membrane AT<sub>2</sub>R recruitment. In contrast, 8-bromo-cAMP administration had no effect on natriuresis or AT<sub>2</sub>R recruitment in SHR. The results demonstrate a primary renal proximal tubule cell AT<sub>2</sub>R natriuretic defect in SHR that may contribute to the development of hypertension. Since the defect is abrogated by exogenous intrarenal cGMP, the renal cGMP pathway may represent a viable target for the treatment of hypertension. Visual Overview: An online visual overview is available for this article.
Medical subject headings
- Hypertension
- Kidney Tubules, Proximal
- Natriuresis
- Receptor, Angiotensin, Type 2